Last $1.93 USD
Change Today +0.01 / 0.52%
Volume 1.9M
AMRN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

amarin corporation plc -adr (AMRN) Snapshot

Open
$1.92
Previous Close
$1.92
Day High
$1.95
Day Low
$1.90
52 Week High
09/6/13 - $7.40
52 Week Low
05/21/14 - $1.28
Market Cap
336.1M
Average Volume 10 Days
2.4M
EPS TTM
$-1.03
Shares Outstanding
174.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARIN CORPORATION PLC -ADR (AMRN)

amarin corporation plc -adr (AMRN) Related Businessweek News

No Related Businessweek News Found

amarin corporation plc -adr (AMRN) Details

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

185 Employees
Last Reported Date: 02/27/14
Founded in 1989

amarin corporation plc -adr (AMRN) Top Compensated Officers

Chief Executive Officer, President, Assistant...
Total Annual Compensation: $395.2K
Senior Vice President and President of Resear...
Total Annual Compensation: $384.3K
Head of Development and Senior Vice President
Total Annual Compensation: $360.5K
Chief Compliance Officer, Senior Vice Preside...
Total Annual Compensation: $358.0K
Compensation as of Fiscal Year 2013.

amarin corporation plc -adr (AMRN) Key Developments

Amarin Corporation plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Net Cash Outflows Guidance for the Third Quarter and Full Year 2014

Amarin Corporation plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported product revenues of $12,606,000 against $5,500,000 a year ago. Operating loss was $25,240,000 against $48,794,000 a year ago. Income from operations before taxes was $15,734,000 against loss from operations before taxes of $39,709,000 a year ago. Net income was $15,323,000 or $0.08 per diluted share against net loss of $39,774,000 or $0.34 per diluted share a year ago. Adjusted net loss for EPS - non GAAP was $23,433,000 or $0.14 per basic and diluted share against $54,528,000 or $0.36 per basic and diluted share a year ago. Net product revenues underlying growth are broader productivity increases, as achieved this growth with lower SG&A costs than a year ago. The improvement of net cash outflow to $13.8 million as compared to $52.4 million in second quarter of 2013. For the six months, the company reported product revenues of $23,573,000 against $7,842,000 a year ago. Operating loss was $50,811,000 against $108,844,000 a year ago. Loss from operations before taxes was $9,821,000 against $105,124,000 a year ago. Net loss was $10,657,000 or $0.07 per diluted share against $101,932,000 or $0.77 per diluted share a year ago. Adjusted net loss for EPS - non GAAP was $51,921,000 or $0.30 per basic and diluted share against $115,885,000 or $0.77 per basic and diluted share a year ago. The company anticipates that third quarter of 2014 net cash outflows from operations will exceed second quarter of 2014 net cash outflows. The company continue to estimate that during 2014, as a whole, net cash outflows will be less than $80 million.

Amarin Corporation Seeks Acquisitions

Amarin Corporation plc (NasdaqGM:AMRN) has filed a shelf registration in the amount of $300 million. Amarin Corporation intends to use a portion of the proceeds to pay off outstanding indebtedness, if any, and/or acquire or invest in complementary businesses, products and technologies.

Amarin Corporation plc to Report Q2, 2014 Results on Aug 07, 2014

Amarin Corporation plc announced that they will report Q2, 2014 results on Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMRN:US $1.93 USD +0.01

AMRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $44.73 USD +0.25
BioMarin Pharmaceutical Inc $71.22 USD +1.60
Dendreon Corp $1.36 USD 0.00
Enzymotec Ltd $8.76 USD -0.11
Jazz Pharmaceuticals PLC $162.92 USD +0.21
View Industry Companies
 

Industry Analysis

AMRN

Industry Average

Valuation AMRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARIN CORPORATION PLC -ADR, please visit www.amarincorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.